Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 18

Results For "Ltd"

1138 News Found

CuraTeQ Biologics completes Phase 3 clinical study for Denosumab biosimilar
Clinical Trials | September 19, 2025

CuraTeQ Biologics completes Phase 3 clinical study for Denosumab biosimilar

Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints


Nanyang Biologics, NVIDIA, HPE & Equinix to launch AI drug discovery platform
Digitisation | September 16, 2025

Nanyang Biologics, NVIDIA, HPE & Equinix to launch AI drug discovery platform

Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.


Dr. Reddy’s launches novel molecule ‘Tegoprazan’ in India
News | September 16, 2025

Dr. Reddy’s launches novel molecule ‘Tegoprazan’ in India

Tegoprazan, a novel patented molecule indicated for acid-related gastrointestinal diseases, is launched in India under the brand name PCAB


Apollo Hospitals acquires IFC’s 3% share in Apollo Health and Lifestyle for Rs. 1,254 Cr
News | September 13, 2025

Apollo Hospitals acquires IFC’s 3% share in Apollo Health and Lifestyle for Rs. 1,254 Cr

AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool


Briefs: Torrent Pharmaceuticals and Hemant Surgical Industries
News | September 12, 2025

Briefs: Torrent Pharmaceuticals and Hemant Surgical Industries

Hemant Surgical Industries receives order


Dr. Reddy’s acquires J&J’s Stugeron portfolio to foray into anti-vertigo segment
News | September 11, 2025

Dr. Reddy’s acquires J&J’s Stugeron portfolio to foray into anti-vertigo segment

The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions


Mankind Pharma gets CDSCO nod to begin Phase 1 trials of novel Autoimmune drug candidate MKP11093
Drug Approval | September 10, 2025

Mankind Pharma gets CDSCO nod to begin Phase 1 trials of novel Autoimmune drug candidate MKP11093

MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile